Skip to main content

Market Overview

Oppenheimer Bullish On Eiger Biopharmaceuticals Shares, Sees 71% Upside

Oppenheimer Bullish On Eiger Biopharmaceuticals Shares, Sees 71% Upside

Oppenheimer said Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) has lots of legs to run on given multiple data catalysts over the next 12–18 months and early human POC data in hepatitis D and hypoglycemia.

Drug Pipeline

Eiger's lead asset, Sarasar, is a farnesyltransferase inhibitor in development to treat hepatitis D. Eiger is also developing Exendin (9-39) as a treatment for hypoglycemia occurring after bariatric surgery, and Bestatin for pulmonary arterial hypertension and lymphedema.

Oppenheimer noted that HDV infection leads to hepatitis D, which is the most aggressive form of hepatitis and has no FDA-approved treatments. Sarasar and IFN treatment decrease HDV RNA levels, and Eiger is investigating the optimum dose and combination regimen in various Phase 2 trials, expected to read out in 2016/2017.

Related Link: Five Prime Therapeutics' FPA144 Receives FDA Orphan Drug Status

"We recommend owning Eiger ahead of these upcoming data readouts as we expect the shares will positively reflect the clinical development progress," analyst Carlos Solorzano wrote in a note.

Solorzano, who has started the coverage of the stock with an Outperform rating and $34 price target, noted that Stanford-run studies showed Exendin (9-39) can normalize the hypoglycemic response in Roux-en-Y patients.

Eiger is currently testing a proprietary subcutaneous formulation of Exendin in hypoglycemic patients, with data expected by the end of 2016.

In addition, Eiger is conducting a Ph2 trial in PAH patients investigating the efficacy of Bestatin over SOC on pulmonary vascular resistance. Data from this trial is expected in 2017.

Further, the analyst noted there is patent-pending pre-clinical evidence of efficacy for Bestatin in lymphedema, and Eiger expects to report data from its Phase 2 ULTRA trial in 2017.

Future Tailwinds

Following are the upcoming catalysts for the stock:

  • 2Q16: Begin Phase 2 LIBERTY trial of Bestatin in PAH
  • 2Q16: Begin Phase 2 ULTRA trial of Bestatin in lymphedema
  • 4Q16: Report data from Phase 2 MAD study of subcutaneous Exendin (9-39) in RYGB patients
  • 2H16: Begin monotherapy Phase 2 trial of pegylated interferon lambda in hepatitis D
  • 2017: Report top-line data from LIBERTY and ULTRA trials

Meanwhile, the analyst expects Eiger to report a loss of $6.81 a share for 2016 and $5.13 a share for 2017.

At the time of writing, shares of Eiger were down 0.35 percent at $19.84.

Latest Ratings for EIGR

Apr 2020WedbushMaintainsOutperform
Jan 2020Ladenburg ThalmannMaintainsBuy
Jun 2019CitigroupInitiates Coverage OnBuy

View More Analyst Ratings for EIGR
View the Latest Analyst Ratings


Related Articles (EIGR)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

QSRNorthcoast ResearchInitiates Coverage On
DQGLJ ResearchInitiates Coverage On22.1
TCMaxim GroupDowngrades
GLNGB of A SecuritiesDowngrades
LMNXPiper SandlerDowngrades37.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at